0000000000367697

AUTHOR

Lawrence A. Leiter

showing 4 related works from this author

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial.

2021

Digital

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodErectile DysfunctionlawInternal medicineDiabetes mellitusInternal MedicinemedicineHumansHypoglycemic Agents030212 general & internal medicineRisk factorAgedbusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseasePrognosisImmunoglobulin Fc FragmentsErectile dysfunctionDiabetes Mellitus Type 2Cardiovascular DiseasesDulaglutideFemalebusinessBiomarkersmedicine.drugFollow-Up StudiesThe lancet. Diabetesendocrinology
researchProduct

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with an…

2020

Digital

medicine.medical_specialtyProportional hazards modelbusiness.industryHazard ratioType 2 diabetes030204 cardiovascular system & hematologyCardiovascular diseasemedicine.diseasePlaceboMetforminMetformin03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicineGLP-1-based therapymedicineDulaglutide030212 general & internal medicinePrediabetesMortalityMorbidityCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean Heart Journal
researchProduct

Design and baseline characteristics of participants in the R esearching cardiovascular E vents with a W eekly IN cretin in D iabetes ( REWIND ) trial…

2017

The aim was to determine the effects of dulaglutide, a synthetic once-weekly, injectable human glucagon-like peptide 1 analogue that lowers blood glucose, body weight, appetite and blood pressure, on cardiovascular outcomes. People with type 2 diabetes, aged ≥50 years, with glycated haemoglobin (HbA1c) ≤9.5%, and either a previous cardiovascular event, evidence of cardiovascular disease or ≥2 cardiovascular risk factors were randomly allocated to a weekly subcutaneous injection of either dulaglutide (1.5 mg) or placebo and followed within the ongoing Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial every 3 to 6 months. The primary cardiovascular outcome is…

medicine.medical_specialtybusiness.industryEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes030204 cardiovascular system & hematologymedicine.diseaseClinical trial03 medical and health sciences0302 clinical medicineEndocrinologyBlood pressureDiabetes mellitusInternal medicineHeart failureInternal MedicinemedicinePhysical therapyDulaglutideMyocardial infarctionbusinessStrokemedicine.drugDiabetes, Obesity and Metabolism
researchProduct

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

2020

Digital

AdultMalemedicine.medical_specialtyRecombinant Fusion ProteinsGlucagon-Like Peptides030209 endocrinology & metabolismType 2 diabetesPlacebolaw.invention03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHumansHypoglycemic AgentsCognitive DysfunctionRisk factorAgedbusiness.industryHazard ratioMontreal Cognitive AssessmentMiddle Agedmedicine.diseaseImmunoglobulin Fc FragmentsTreatment OutcomeDiabetes Mellitus Type 2Digit symbol substitution testFemaleDulaglutideNeurology (clinical)business030217 neurology & neurosurgerymedicine.drug
researchProduct